# Anandamide in First-Episode Psychosis: Associations with Symptoms and Inflammation > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/anandamide-in-first-episode-psychosis-associations-with-symptoms-and-inflammation/ > **Published:** 2026-08-09T07:26:15-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:17:06-04:00 > **Clinical Summary:** Anandamide dysregulation linked to psychosis symptoms and inflammation. Clinical implications for cannabis use and psychotic illness. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyMental HealthResearchAnxietySafetyTHCPolicy Why This Matters Elevated anandamide levels in first-episode psychosis patients may represent a biomarker for disease severity and inflammatory status, helping clinicians identify which patients need more aggressive intervention or monitoring. Understanding the endocannabinoid system’s role in psychosis could inform development of novel therapeutics that modulate anandamide rather than blocking all cannabinoid signaling, potentially offering better efficacy and fewer [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) than current antipsychotics. Clinicians should counsel patients with psychotic disorders about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) risks, as exogenous cannabinoids may exacerbate the underlying anandamide dysregulation already present in their condition. Clinical Summary # Clinical Summary This study examined anandamide, an endogenous cannabinoid, in patients experiencing first-episode psychosis, investigating whether alterations in this signaling system correlate with psychotic symptoms and inflammatory markers. The findings suggest that dysregulation of the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) may contribute to the pathophysiology of psychosis through mechanisms involving neuroinflammation, potentially explaining why some [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) precipitates psychotic episodes while cannabidiol (a non-intoxicating cannabinoid) shows promise as an antipsychotic agent. Understanding anandamide’s role in psychosis is particularly important for clinicians prescribing cannabis or cannabinoid therapies, as this knowledge helps explain individual variability in psychotic responses and identifies potential biomarkers for patient stratification. These findings support more nuanced clinical approaches that differentiate between cannabinoids with psychotogenic potential (THC) and those with potentially neuroprotective properties (CBD), while highlighting the need to screen for [psychosis risk](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) before recommending cannabis products. Clinicians should counsel patients with first-episode psychosis or family histories of psychotic disorders to avoid THC-predominant products and consider baseline endocannabinoid assessment when evaluating cannabinoid therapeutic options. Dr. Caplan’s Take “This is an interesting mechanistic observation about anandamide and psychosis, but we’re looking at associations in a relatively small population—we need replication in larger cohorts before we can draw firm conclusions about causation or clinical implications for how we manage these patients.” Clinical Perspective 🧠 Elevated anandamide levels in first-episode psychosis patients warrant clinical attention as a potential biomarker linking cannabinoid system dysfunction to symptom severity and inflammatory pathways, though the cross-sectional nature of such studies limits causal inference. The endocannabinoid system’s role in psychotic symptoms remains incompletely understood, and individual variation in baseline anandamide levels, [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) history, and genetic factors may confound the relationship between this biomarker and clinical presentation. Given that cannabis use itself modulates endocannabinoid signaling and can precipitate or worsen psychotic symptoms, distinguishing primary endocannabinoid abnormalities from substance-related changes in first-episode patients requires careful collateral history and longitudinal investigation. While anandamide measurement is not yet standard [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/), understanding these mechanistic associations may eventually inform personalized risk stratification for psychosis and guide consideration 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Anandamide%20in%20First-Episode%20Psychosis%3A%20Associations%20with%20Symptoms%20and%20Inflammation%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72966)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72966)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Anandamide%20in%20First-Episode%20Psychosis%3A%20Associations%20with%20Symptoms%20and%20Inflammation%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72966)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Daily Digest: Cannabis Adolescent Psychiatric Risk Data Study](https://cedclinic.com/cannabis-adolescent-psychiatric-risk-data-study/) - [Daily Digest: Cannabis Impact on Adolescent Brain in 2026](https://cedclinic.com/2026-cannabis-adolescent-brain-vulnerability/) 📰 Source: [https://pmc.ncbi.nlm.nih.gov/articles/PMC13441908/](https://pmc.ncbi.nlm.nih.gov/articles/PMC13441908/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).